These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9869172)

  • 1. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH; Kottke-Marchant K; Brooks LM; Topol EJ
    Thromb Haemost; 1998 Dec; 80(6):989-93. PubMed ID: 9869172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.
    Haas S; Walenga JM; Jeske WP; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 1():67-75. PubMed ID: 10357155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.
    Jeske WP; Walenga JM; Szatkowski E; Ero M; Herbert JM; Haas S; Bakhos M
    Thromb Res; 1997 Nov; 88(3):271-81. PubMed ID: 9526947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
    Untch B; Ahmad S; Messmore HL; Schultz CL; Ma Q; Hoppensteadt DA; Walenga JM; Fareed J
    Thromb Res; 2002 Apr; 106(2):149-56. PubMed ID: 12182915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.
    Herbert JM; Savi P; Jeske WP; Walenga JM
    Thromb Haemost; 1998 Aug; 80(2):326-31. PubMed ID: 9716161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.
    Kanemitsu S; Nishikawa M; Onoda K; Shimono T; Shimpo H; Yazaki A; Tanaka K; Shiku H; Yada I
    J Thorac Cardiovasc Surg; 2003 Aug; 126(2):428-35. PubMed ID: 12928640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
    Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.